Biotherapeutics News and Research

RSS

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announce today that they have initiated the first-in-human clinical study of OBT357 (MEN1112), a novel enhanced antibody for the treatment of acute myeloid leukemia (AML).

25 Nov 2014

Asterias, CIRM sign NGA to begin AST-OPC1 study for complete cervical spinal cord injury

Asterias Biotherapeutics, Inc. announced today that the Company has signed a Notice of Grant Award (NGA) with the California Institute of Regenerative Medicine (CIRM), effective October 1, 2014.

20 Oct 2014

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer.

11 Sep 2014

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias Biotherapeutics Inc. has received clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury.

27 Aug 2014

23andMe, Pfizer partner to explore genetic factors associated with IBD

23andMe, the leading personal genetics company today announced an agreement with Pfizer Inc. in which the companies will aim to enroll 10,000 people with Inflammatory Bowel Disease (IBD) in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD.

12 Aug 2014

Researchers plan to develop vaccine into a type of antibody serum therapy

By many estimates, an Ebola vaccine could be available in humans as early as next year. But will it be the right one? There are a number of vaccines in development and each is in a race to prove that it is most effective, safe and that it will protect the largest number of people.

7 Aug 2014

Wyatt Technology highlights protein-protein interactions study investigated by dynamic light scattering

Wyatt Technology Corporation, the world leader in absolute macromolecular characterization instrumentation, is pleased to highlight a study recently authored by Martin Skov Neergaard from the Faculty of Health and Medical Sciences at the University of Copenhagen, “Protein-Protein Interactions Investigated by DLS: Determination at High and Low Protein Concentration.”

From Waters | Wyatt Technology 1 Jul 2014

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that it has initiated the Phase III trial of DCVax-L in Germany.

10 Jun 2014

Thrasos presents positive results of THR-184 compound for treatment of acute kidney injury

Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, today presented preclinical results showing that its lead development compound THR-184 can effectively protect against loss of kidney function following acute ischemic injury in rat.

4 Jun 2014

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results and operational highlights for the quarter ended March 31, 2014.

15 May 2014

Baxter plans to create two independent global healthcare companies

Baxter International Inc. today announced plans to create two separate, independent global healthcare companies -- one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. Both will be global leaders in their respective markets.

From Baxter International Inc. 27 Mar 2014

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).

18 Mar 2014

ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that it has been awarded a €3 million grant from the Flemish agency for Innovation by Science and Technology.

10 Mar 2014

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).

19 Feb 2014

Eleven Biotherapeutics announces pricing of initial public offering of common stock

Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions.

6 Feb 2014

Immunocore, MedImmune sign oncology research collaboration and licensing agreement

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.

8 Jan 2014

Oxygen Biotherapeutics announces publication of Phase 3 trial protocol for levosimendan

Oxygen Biotherapeutics, Inc. ("OBI") a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the protocol of their phase 3 trial for levosimendan has been published on ClinicalTrials.gov, "Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Heart Surgery on Cardiopulmonary Bypass."

7 Jan 2014

BBC TV report profiles NW Bio's DCVax-L Phase III trial for GBM brain cancer

Northwest Biotherapeutics, Inc.("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the British Broadcasting Company (BBC) TV network has broadcast a report profiling the first European patient in the Company's Phase III clinical trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), the most common and aggressive form of brain cancer.

31 Dec 2013

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under its Series B financing. In this round, investors Amgen Ventures, Celgene Corporation, and EcoR1 Capital, joined existing investors Alexandria Venture Investments, DAG Ventures, Domain Associates, and Kleiner Perkins Caufield & Byers.

17 Dec 2013

SillaJen executes definitive merger agreement to acquire Jennerex

SillaJen, Inc., a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, announced today that it had executed a definitive merger agreement to acquire San Francisco-based Jennerex, Inc.

26 Nov 2013